Cabergoline 0.50 mg
Product Overview
| Generic Name | Cabergoline 0.50 mg |
| Brand Name(s) | Dostinex, Cabgolin |
| Category | Endocrine |
| Form | 4 count oral tablets |
| Strength | 0.50 mg |
| Therapeutic Class | Treatment of hyperprolactinemia; also uses in Parkinson’s disease and lactation suppression |
| ATC Code | G02CB03 |
Manufacturing & Regulatory
| Manufacturer | Pfizer, Sun Pharmaceutical Ltd |
| GMP Compliance | WHO-GMP |
| DMF/CEP | Manufacturer-specific, not public |
| COFEPRIS | 010.000.1094.01 |
| Free Sale Certificate | Yes, available as COPP/CPP |
Logistics & Export
| MOQ | 10 Units |
| Shelf Life | 24 Months |
| Storage | Store at 20–25 °C |
| Incoterms | EXW |
| Lead Time | 7 - 10 Business Days |
Documentation Available Upon Request
| Certificate of Analysis (PDF) | Supplied per batch upon request |
| SDS-Safety Data Sheet (PDF) | Upon Request, not publicly posted |
| CTD Summary (PDF) | Full CTD dossier proprietary; available under commercial agreement/license |
Special Notes
Cabergoline is indicated for treatment of hyperprolactinemia (e.g. prolactinomas, amenorrhea, infertility, galactorrhea) at initial adult dose of 0.25 mg twice weekly with titration up to 1 mg twice weekly as needed. Mechanism: long‑acting dopamine D₂ agonist inhibiting prolactin secretion.